Sexual dimorphism in the effect of concomitant progesterone administration on changes caused by long-term estrogen treatment in pituitary hormone immunoreactivities of rats

Andrea Heinzlmann1, Katalin Köves1, Magdolna Kovács2, Valér Csernus2

1 Department of Human Morphology and Developmental Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
2 Department of Human Anatomy, Pécs University, Pécs, Hungary

Source of support: Department of Human Morphology and Developmental Biology, Semmelweis University, Budapest and OTKA grant T49014 to MK

Summary

Background: Since in clinical practice long-term estrogen (E) treatment is frequently applied, our aim was to study the effect of concomitant progesterone (P) administration on changes caused by long-term estrogen treatment in the secretion of LH, FSH, PRL and GH.

Material/Methods: Diethylstilbestrol (DES), P or both in silastic capsules were implanted under the skin of prepubertal Sprague-Dawley male and female rats. Animals survived for two or five months. We have also studied whether the changed hormone secretion caused by DES can return to normal level 1 or 2 months after removing DES capsule.

Results: 1.) The males more rapidly responded than females with decreasing basal LH release upon treatments. The basal FSH release was decreased only in males. The effect of DES persisted in males; however, in females basal LH and FSH levels were upregulated after removal of DES capsule. 2.) The basal GH levels were low in each group. The body weight and length were depressed by DES in both genders and P little blunted this effect. The body weight and length in males remained low after removal of DES capsule, in females it was nearly similar to intact rats. 3.) There was no sexual dimorphism in the effect of steroids on PRL secretion. In both genders DES extremly enhanced the PRL levels, P prevented the effect of DES. PRL levels returned to intact value after removal of DES influence. 4.) Removal of DES capsule reversed the changes in the immunohistochemical appearance of hormone immunoreactivities.

Conclusions: There was sexual dimorphism in the change of basal gonadotropic hormone and GH secretion but not of PRL upon DES and DES+P treatments. P was basically protective and this role may be mediated by P receptors locally in the pituitary gland.

key words: anterior pituitary • immunohistochemistry • RIA • sexual dimorphism

Abbreviations: ACTH – adrenocorticotropic hormone; DES – diethylstilbestrol; E – estrogen; EB – estradiol benzoate; ecap – empty capsule; ER – estrogen receptor; E2 – estradiol; β FSH folliculus stimulating hormone; GH – growth hormone; GHRH – growth hormone releasing hormone; GnRH – gonadotrop hormone releasing hormone; Ir – immunoreactive; IR – immunoreactivity; LH – luteinizing hormone; NET – norethisterone enantate (synthetic progesterone); P – progesterone; PR – progesterone receptor; PRL – prolactin; TSH – thyrotropic hormone; VIP – vasoactive intestinal polypeptide

Full-text PDF: http://www.medscimonit.com/fulltxt.php?ICID=881440

Word count: 5117
Tables: 3
Figures: 5
References: 62

Author’s address: Andrea Heinzlmann, Department of Human Morphology and Developmental Biology, Faculty of Medicine, Semmelweis University, Túzoltó u. 58, H-1094 Hungary, e-mail: handrea@ana2.sote.hu
Background

It is well known that sexual steroids, estrogen (E) and progesterone (P), among other factors regulate the secretion of pituitary tropic hormones directly acting on pituitary cells and through the central nervous system by a feed-back mechanism. It was demonstrated two decades ago that diethylstilbestrol (DES) induced appearance of prolactin (PRL)-secreting tumors [1].

Estrogen and progesterone receptors (ERs and PRs) were identified in various pituitary hormone secreting cells and in various hypothalamic and extrahypothalamic structures. Both ER and PR have two isoforms. ERα was identified by Koike and his co-workers [2], ERβ was cloned by Kuiper and his co-workers [3]. In a recent publication it was found that ERα is localized in the largest number in lactotropes, and in decreasing number in somatotropes, thyrotropes, gonadotropes. The number of ERβ was much lower and it was identified in somatotropes, lactotropes and gonadotropes. Immunoreactivity of both receptors was present in the nucleus, rough endoplasmic reticulum, secretory granules and in the free cytosol. The intracellular localization was dependent on the stage of estrous cycle [4]. In another study it was shown that ERβ was expressed by folliculin stimulating hormone (FSH) cells [5]. A and B isoforms of PR were demonstrated in the anterior lobe using RT-PCR technique [6] and immunohistochemistry [7]. The predominant form is the A-isofrom (PRA). In rat PR immunostaining was seen in the nuclei of gonadotropes. Both ERs and PRs were also shown in the central nervous system including hypothalamic structures [8–11].

Besides classical hormones, the anterior pituitary also produces many other substances such as neurotransmitters, neuropeptides, and growth factors [12]. The classical pituitary hormones act far from the site of production and reach their targets via the general circulation. The small peptide molecules act in auto- and paracrine manners [13,14].

The effect of E and P on rat pituitary tropic hormone levels was investigated in vivo and in vitro models [7,15–18]. In our previous experiment [19] long-term E treatment (implantation of DES capsule under the skin of neck) depressed the number of luteinizing hormone (LH) and thyroid stimulating hormone (TSH) cells, it enhanced the number of cells (the cells formed prolactinoma), it enhanced the size of growth hormone (GH) cells and it did not influence the number of adrenocorticotropic (ACTH) cells. DES extremely enhanced the number of vasoactive intestinal polypeptide (VIP) cells and induced appearance of VIP-oma. It was also demonstrated that E enhanced the VIP expression in the anterior pituitary by six times as compared with intact rats [20].

With the use of haemolytic plaque assay it was demonstrated that a chronic E treatment increased the percentage of PRL secreting cells and the amount of secreted PRL; however, there was a decrease in both the percentage of GH secreting cells and the amount of secreted GH. Following the haemolytic plaque assay in situ hybridization revealed that estradiol β (E2) increased the PRL mRNA while it decreased the GH mRNA [16]. This research group did not find any colocalization between GH and PRL expression in control male rat pituitary cell culture; however, in E2 treated culture about 10% of PRL secreting cells contained GH mRNA as well. It was also demonstrated that the effect of E in the pituitary is mediated through ERα [21].

The data in the literature concerning the effect of P on pituitary hormone secretion is controversial and not so abundant. The protective effect of P on inducing undesired changes was observed about twenty-five years ago. It was demonstrated that P was able to reduce the size of E induced mammary tumor [22]. The protective role of P is also used to prevent preterm birth when being applied as vaginal suppository [23]. Genazzani and his co-workers [24] analysed how P and various synthetic progestins modulate the effect of E on hypothalamic gonadotropin-releasing hormone (GnRH) and on pituitary LH and PRL concentrations in ovariec-tomized rats. Two-week steroid treatments were applied. It was found that P and norethisterone enanthate (NET, synthetic progestin) reversed the depression of hypothalamic GnRH induced by the estradiol benzoate (EB) and elevated its level. Both P and NET blocked the EB induced increase of pituitary LH, and the plasma LH levels remained low. Progestins alone did not influence the PRL levels but reversed the EB induced increase.

In clinical practice sexual steroid treatment is a very common medical procedure. Steroid hormone contraception was suggested about seventy years ago [25]. It is well known that administration of E, P or the combination of E and P prevents the LH surge and the ovulation [26–29]. Sexual steroids are also applied to synchronize the ovarian cyclicity, to maintain the endometrium during pregnancy [30,31]. E is even recently used as replacement therapy after surgical removal of ovaries or in menopause as well [32–34]. In men E is used to treat prostatic cancer [35].

The aim of our present work was to further clarify the way how the concomitant P administration affected the changes in the anterior pituitary caused by long-term estrogen treatment. Long-term steroid treatments in experimental animals, similar to those applied in the human practice was rarely found in the literature. We decided to imitate the long-term clinical treatments. Two- and five-month survivals after implantation of hormones were chosen, both are long time in the life of rats. The animals were three and six-month-old when they were sacrificed. Three-month-old rat is a relatively young adult and the six-month-old rats are old. The continuous hormone influence was provided by the implantation of DES and P containing capsules. At the end of experimental periods we have examined LH, FSH, PRL, and GH immunoreactivities in the anterior pituitary gland and basal LH, FSH, PRL and GH plasma levels in rats of both sexes. We have also examined whether removal of DES capsule two months after implantation can reverse the DES induced changes one or two months following the removal.

Material and Methods

Animals

Sprague-Dawley female and male rats were used for our experiments. They were kept in a light (light on at 5 h and off at 19 h) and temperature (22±2°C) controlled vivarium and fed with standard lab chow and water ad libitum. The treatment of the animals was in accordance with the rules of the „European convention for the protection of vertebrate animals used for experimental and other scientific
purposes”, Strasbourg, 1986. Our protocol was approved by the Department of Animal Health Care, Budapest. Permission number: 37/1999. When the animals were 25 day-old they received empty capsule (ecap), DES, DES + P or just P containing silastic capsule implanted under the skin of the neck in the subcutaneous tissue.

**Preparation of the hormone containing capsules**

Silastic capsules (id 1.55 mm, od 3.13 mm, length 10 mm) (Dow Corning Corporation, Midland, MI) were filled with DES (Sigma, St. Louis, Mo) or P (Sigma) and the ends of the capsules were sealed by Szilofix (Finomvegyszer Szövetkezet, Budapest, Hungary), a silicon based glue. A day after drying, the capsules were used for implantation. The steroids can pass through the wall of the capsule and can exert its effect through the general circulation [36].

**Experimental protocol**

The animals were grouped as follows.

Experiment 1.
1. intact (negative control) rats,
2. ecap (sham operated rats receiving ecap sealed with glue),
3. DES implanted rats,
4. DES+P implanted rats,
5. P implanted rats.

85 female and 79 male rats were included in this experiment. The survival time after implantation was 2 months.

Experiment 2.
Similar groups were included in this experiment (56 females and 56 males) as described in Experiment 1; however, the survival time was 5 months.

Experiment 3.
From 35 DES implanted animals (18 females and 17 males) the DES capsules were removed. Half of these animals was sacrificed 1 month after the removal and the other half was sacrificed 2 months after removal. Age matched controls were also included in all the groups (17 females and 16 males). The data obtained in these groups were compared with those of DES implanted rats and their age matched controls of Experiment 1.

In female rats the opening of the vaginal membrane was recorded. Then vaginal smear was taken daily for two weeks and for another two weeks before sacrificing. Females were handled in this way. The male rats were transferred from their cage to another and back every day for two weeks before sacrificing (handling) to blunt the stress effect.

At the end of the experimental period the body weight (BW) and body and tail length (B+TL) were measured and the animals were sacrificed by decapitation between 9 am and 11 am. The trunk blood was collected, its coagulation was prevented by EDTA (ethylene diamine tetraacetic acid sodium salt, Serva, Heidelberg, Germany). Plasma was used to determine hormone levels. Endocrine organs were weight

**Radioimmunoassay (RIA)**

The trunk blood was centrifugated at 4°C. Plasma was stored at –20°C until determination of pituitary hormones. Iodination was carried out by Chloramine-T method. Separation of the free and bound antigen was made by double antibody method. All hormone kits were obtained from the National Hormone and Peptide Program (NHPP), NIDDK, and Dr. Parlow. Hormone levels were expressed in ng/ml plasma. The mean of two parallel determinations for each animal was subjected to one way analysis of variance (ANOVA) followed by a Student’s t test.

**Immunohistochemistry**

Three animals of each group were anesthetized by ketamine-hydrochloride (75 mg/100g bw) (Sigma, St. Louis, MO) and perfused with 4% paraformaldehyde (Merek, Darmstadt, Germany) in potassium phosphate buffer (KPB) (pH 7.4, 0.1mol). The components were purchased from Sigma (St. Louis, MO). Pituitaries were removed and postfixed overnight. All the pituitaries (fixed in Bouin solution or PFA) were used for immunohistochemistry. After washing in KPB, the pituitaries were immersed in ascending sucrose solution (10–20–30%), then frozen on dry ice. The pituitary sections were rinsed in potassium phosphate buffer (KPB), pH 7.4. The tropic hormones were visualized by indirect fluorescence technique. The following primary antisera were used in our experiment: LH, FSH, GH (dilution 1:500) were raised in guinea pig and obtained from the National Hormone and Peptide Program (NHPP), NIDDK, and Dr. Parlow. PRL antisera (dilution 1:500) was raised in rabbit by Nagy and characterized by Demaria et al. [37]. Fluorescence labeled secondary antibodies were the following: rabbit anti-guinea pig IgG conjugated to FITC (DAKO A/S, Glostrup, Denmark), goat anti-rabbit IgG conjugated to Cy3 (DAKO A/S, Glostrup, Denmark).

Selected sections were double stained for PRL and GH immunoreactivities using fluorescence technique. First PRL staining was carried out using a monoclonal antibody (raised and characterized by Scammell [38] and TRITC conjugat

**RESULTS**

**Vaginal smears**

In intact rats the vaginal membrane opened on 31.36±0.80 day of postnatal life. In all animals implanted with capsule (independently of their hormone content) the vaginal membrane opened earlier. In DES treated rats it happened much earlier than in intact animals (27.50±0.31, p<0.0001), although in animals implanted with ecap, DES+P or P alone the opening was also significantly shifted earlier than in intact rats, 28.36±0.47 (p<0.003) 28.06±0.34 (p<0.0005) and 29.09±0.51...
(p<0.05) day of postnatal life, respectively. Upon DES treatment in the vaginal smear persistent estrus was observed. DES+P did not interrupt the cyclicity but it was irregular and metestrus predominated, ecap and P alone had no effect.

**Effect of treatments on the body weight and body length**

Table 1 shows BW and B+TL in various groups of female and male rats 2 and 5 months after implantation. In DES and DES+P implanted animals BW and B+TL were significantly lower than in control rats 2 months after implantation; however, 5 months after implantation P moderated the effect of DES. P alone slightly decreased BW only in the case of 5-month treatment. When we removed the DES capsule BW and B+TL could not return to intact levels, but the difference was not significant in B+TL of females.

**Effect of treatments on the weight of the endocrine organs**

Table 2 shows the weight of the anterior pituitary and the ovaries in female rats. The weight of anterior pituitaries increased upon DES and DES+P treatments in the case of 2-month survival, but in the case of 5-month treatment P reversed the weight gain. When the DES capsule was removed the weight of pituitaries returned to control level. DES and DES+P extremely decreased the weight of ovaries after 2-month steroid treatment. In the case of 3-month survival P prevented the effect of DES and P alone slightly decreased the weight of ovaries. When DES capsule was removed the weight of ovaries returned to control levels.

**Effect of treatments on the classical pituitary hormone immunoreactivities**

**Radioimmunoassay**

The basal LH level in female rats was depressed by DES treatment (Figure 1A,B), but it become significant only five months after implantation. Progesterone alone had no

---

**Table 1. Body weight (BW) and body and tail length (B+TL) of female and male rats.**

| Group of animals | Female | Male |
|------------------|--------|------|
|                  | BW     | B+TL | BW     | B+TL |
| 2 month survival |        |      |        |      |
| intact (19)      | 244.1±4.19 | 38.50±0.25 | 394.8±12.42 | 44.11±0.28 |
| ecap (12)        | 254.5±13.93 | 39.04±0.39 | 418.8±10.14 | 44.30±0.51 |
| DES (19)         | 144.9±4.25*** | 33.36±0.46*** | 174.2±5.59*** | 33.82±0.34*** |
| DES+P (20)       | 158.8±5.25*** | 32.54±0.43*** | 179.8±6.27*** | 33.98±0.33*** |
| P (15)           | 250.7±6.71 | 37.89±0.50 | 412.0±9.23 | 43.92±0.40 |
| 5 month survival |        |      |        |      |
| intact (10)      | 311.3±7.93 | 41.68±0.58 | 540.7±15.67 | 47.45±0.46 |
| ecap (12)        | 291.9±4.86 | 41.33±0.96 | 497.3±11.20 | 46.28±1.20 |
| DES (11)         | 143.7±4.37*** | 33.09±0.67*** | 178.6±3.17*** | 32.27±2.58*** |
| DES+P (11)       | 239.4±21.06** | 36.80±1.55** | 352.9±52.60** | 41.06±1.75** |
| P (12)           | 285.5±4.36** | 40.50±0.51 | 453.3±30.81* | 47.01±0.34 |
| DES removal      |        |      |        |      |
| intact (19)      | 244.1±4.19 | 38.50±0.25 | 394.9±12.42 | 44.11±0.28 |
| DES (19)         | 144.9±4.25*** | 33.36±0.46*** | 174.2±5.59*** | 33.82±0.34*** |
| intact (8)       | 225.9±7.46 | 39.03±0.29 | 422.6±19.43 | 46.33±0.66 |
| DES 1 m (9)      | 200.1±14.41 | 36.91±0.29*** | 275.5±14.85*** | 40.88±1.14*** |
| intact (9)       | 273.8±9.94 | 40.17±0.38 | 511.6±18.80 | 46.87±0.49 |
| DES 2 m (9)      | 247.7±6.10*  | 38.52±0.82 | 391.6±14.89*** | 43.32±0.58*** |

* p<0.01; ** p<0.001; *** p<0.0001; 1 m – one month survival after removal of DES capsule; 2 m – two month survival after removal of DES capsule; the numbers in brackets indicate the number of animals in each experimental group.
Table 2. Weight of anterior pituitary and ovaries of female rats.

| Group of animals | Anterior pituitary (mg) | Ovaries (mg) |
|------------------|------------------------|--------------|
| 2 month survival |                        |              |
| intact (19)      | 10.8±0.24              | 100.1±5.19  |
| ecap (12)        | 11.0±0.46              | 95.2±3.37   |
| DES (19)         | 16.9±1.56***           | 56.2±7.61***|
| DES+P (20)       | 14.8±1.10**            | 44.3±6.02***|
| P (15)           | 10.0±0.41              | 94.8±2.36   |
| 5 month survival |                        |              |
| intact (10)      | 13.3±0.49              | 132.2±13.11 |
| ecap (12)        | 12.3±0.41              | 123.6±8.45  |
| DES (11)         | 27.9±4.73***           | 33.0±6.92***|
| DES+P (11)       | 12.6±0.84              | 115.0±13.86 |
| P (12)           | 12.3±0.68              | 99.5±4.00*  |
| DES removal      |                        |              |
| intact (19)      | 10.8±0.24              | 100.1±5.19  |
| DES (19)         | 16.9±1.56***           | 56.2±7.61***|
| intact (8)       | 11.4±0.46              | 100.7±7.54  |
| DES 1 m (9)      | 12.6±0.75              | 102.1±6.29  |
| intact (9)       | 13.8±0.80              | 96.4±3.45   |
| DES 2 m (9)      | 12.2±0.54              | 94.7±4.66   |

*p<0.01; **p<0.001; ***p<0.0001; 1 m – one month survival after removal of DES capsule; 2 m – two month after removal of DES capsule, the numbers in brackets indicate the number of animals in each experimental group.

The basal FSH level in female rats was not significantly influenced in groups of 2- or 5-month survival (Figure 2A,B); but 2 months after the removal of DES capsule FSH was significantly higher than in the age-matched control rats (Figure 2C). In male rats both DES and DES+P treatment depressed the FSH levels two months after implantation (Figure 2D) but five months after the implantation the FSH levels were similar in each group (Figure 2E), likewise the females. After the removal of DES capsule the FSH levels remained lower and did not return to control values (Figure 2F).

The basal PRL levels showed very similar pattern in both female and male rats. DES extremely enhanced the PRL levels (Figure 3A,B and D,E). Two months after implantation P blunted the effect of DES (Figure 3A, D) and five months after implantation P completely reversed the effect of DES (Figure 3B, E). P alone had no effect on the PRL levels (Figure 3A,B and D,E). Removal of DES capsule gradually restored the PRL levels (Figure 3C,F).

The basal GH levels were very contradictory (Figure 4A–F). In females DES and DES+P treatment decreased the level (Figure 4A,B); however, it was significant only after 2-month treatment (Figure 4A). P alone did not influence the GH level 2 months after implantation (Figure 4A) but it decreased after 5 months (Figure 4B). When the DES capsule was removed GH levels reached the control value in one month and by the end of 2-month survival after removal and it was even higher than in controls (this elevation was not statistically significant) (Figure 4C). In male rats we did not find significant difference in any groups (Figure 4D,F).

Immunohistochemistry

The quantitative measurements obtained with RIA were confirmed with the qualitative observations provided by immunohistochemistry.

Distribution of immunoreactive cells in intact rats

In the anterior lobe of intact rats the distribution of tropic hormone immunoreactive cells is very characteristic (Figure 5A–H). The density of LH and FSH immunoreactive cells is much higher in the gonadotropic zone that is in the anterior pole of the anterior pituitary (Figure 5A–D). PRL is evenly distributed all over the anterior lobe (Figure 5E,F). GH immunoreactive cells are almost absent in the anterior pole of intact rats. Everywhere else they are evenly distributed (Figure 5G,H).

Distribution of immunoreactive cells in steroid treated rats

Steroid treatments differently influenced the immunoreactivity of the four hormone producing cells.

The number of LH and FSH cells decreased in both female and male rats. The effect of DES was more pronounced five than two months after DES implantation. Figure 5I and J show LH immunoreactive cells in the anterior pituitary of DES treated female rats after 2- and 5-month treatments, respectively. When P was implanted together with DES, the effect of DES was nearly prevented by P (Figure 5K,L). It seemed that only the density of gonadotropes in the rostral pole of the anterior lobe was lower than in intact rats. The appearance of LH and FSH immunoreactivities in male rats was very similar to that of females (not shown). P alone did not influence the LH and FSH immunoreactivities in the anterior lobe of both sexes (not shown).

DES enhanced the number and the size of PRL cells in both female and male rats (Figure 5M–O and Q, male). In intact rats these cells are cup-shaped (Figure 5N). In DES treated rats the cells are large, ovoid or rounded, and their diameter is nearly double than that of intact rats already after two-month steroid influence (Figure 5O). Figure 5P shows PRL cells from a male animal with DES+P treatment (2-month survival). In these animals...
the size of the cells were only moderately enhanced compared to control rats and they lost their cup-shaped appearance. When the animals were treated with DES for 5 months prolactinomas developed. Figure 5Q shows a well-developed prolactinoma. P prevented the effect of DES on PRL. The immunostaining was similar to control rats (Figure 5R). P alone did not affect the PRL immunostaining (not shown).

GH cells did not show a pronounced change either in male or female rats upon 2-month DES treatment but the distribution of these cells was very characteristic in animals with 5-month DES treatment. GH cells were completely missing in areas resembling prolactinomas (Figure 5S). Double labeling immunohistochemistry confirmed this observation (Figure 5T). In DES+P treated rats GH immunostaining was very similar to intact rats. The only difference was observed in the distribution of GH cells. They could be also observed in the anterior pole of the anterior pituitary gland (Figure 5U), this is the region where they are missing in intact rats.

Implantation of ecap did not alter the immunostaining of pituitary tropic hormone producing cells.

Effect of the removal of DES capsule on the distribution of immunoreactive cells

The removal of DES capsule from the animals restored the density and distribution of all the four hormone-producing cells already in one month. One or 2 months after the removal of DES capsule the appearance of immunostaining was similar to those of intact rats (Figure 5V–X).

Discussion

In the present experiment we tried to imitate long-term steroid treatments which are frequently used in clinical practice. It is well known that continuous E or combined E + P administration prevents the ovulation. The modern contraceptive medication is based on these observations [26,39–41]. Nowadays high percent of girls around puberty uses contraceptive hormones [42], in some cases the steroids are used as medication of acne vulgaris in this early age [43]. In men E preparations (DES) are usually used in adult age to treat prostate cancer [35,44]. E is also used to ameliorate the postmenopausal syndromes and osteoporosis [34].

Our experiments provide new informations concerning the effect of long-term E and concomitant P treatments on the

| Group of animals | Anterior pituitary (mg) | Testes (mg) | Seminal vesicle (mg) |
|------------------|------------------------|------------|---------------------|
| **2 month survival** |                         |            |                     |
| intact (22)      | 9.5±0.47               | 2651±275.9 | 1008±84.57          |
| ecap (11)        | 10.0±0.49              | 3247±112.8 | 1367±95.5**         |
| DES (19)         | 19.7±1.36***           | 284.6±23.14*** | 190.5±8.96***     |
| DES+P (13)       | 16.3±0.72***           | 352.0±26.33*** | 171.8±9.82***     |
| P (14)           | 10.0±0.35              | 3244±167.3*  | 1362±66.80**        |
| **5 month survival** |                         |            |                     |
| intact (9)       | 10.1±0.99              | 3357±112.9 | 1869±261.7          |
| ecap (8)         | 11.1±0.58              | 3249±151.8 | 1864±123.1          |
| DES (14)         | 33.2±5.33**            | 145.3±26.30*** | 243.6±27.97***   |
| DES+P (12)       | 14.0±1.62              | 2125±536.5*  | 1305±266.7          |
| P (13)           | 10.9±0.81              | 3603±82.70  | 1740±120.6          |
| **DES removal**  |                         |            |                     |
| intact (22)      | 9.5±0.47               | 2651±275.9 | 1008±84.57          |
| DES (19)         | 19.7±1.36***           | 284.6±23.14*** | 190.5±8.96***     |
| intact (9)       | 11.5±0.43              | 3600±178.7  | 1356±165.1          |
| DES 1 m (8)      | 10.6±0.42              | 2411±198.2*** | 766.7±92.80**  |
| intact (7)       | 11.7±0.61              | 4014±128.0  | 1886±295.5          |
| DES 2 m (9)      | 12.6±0.68              | 3370±222.6*  | 1490±237.3          |

* p <0.01; ** p<0.001; *** p <0.0001; 1 m – one month survival after removal of DES capsule, 2 m – two month survival after removal of DES capsule, the numbers in brackets indicate the number of animals in each experimental group.
Figure 1. LH plasma levels in various experimental groups. (A) shows LH levels in female rats with two-month survival after the implantation of capsules, (B) with five-month survival, and (C) shows LH in the animals two months after the implantation of DES capsule, and one and two months after the removal of DES capsule. (D–F) show LH data in male rats of similar experimental groups as in females. Numbers in the columns or above them indicate the number of animals included in the given group. Abbreviations: DES – diethylstilbestrol; ecap – empty capsule; P – progesterone.

Figure 2. FSH plasma levels in various experimental groups. (A) shows FSH levels in female rats with two-month survival after the implantation of capsules, (B) with five-month survival, and (C) shows FSH in the animals two months after the implantation of DES capsule, and one and two months after the removal of DES capsule. (D–F) show FSH data in male rats of similar experimental groups as in females. Numbers in the columns or above them indicate the number of animals included in the given group. Abbreviations: DES – diethylstilbestrol; ecap – empty capsule; P – progesterone.
changes caused by E, and the consequence of the removal of E capsule after two months of its implantation on pituitary LH, FSH, PRL and GH synthesis and release.

New data are as follows:

1. There is sexual dimorphism in the change of basal LH and FSH release upon DES and combined DES+P treatments. The male rats more rapidly responded than female rats with decreasing basal LH release upon E and E+P treatments. The effect of P was ambiguous. It was protective in five-month treated females but not in males. The basal FSH release was decreased only in male rats and later it was recovered. Neither LH, FSH nor the weight of testes and seminal vesicles restored in male rats after the removal of DES capsule. However, the LH level and the weight of seminal vesicles were not significantly lower than in intact rats. It means that the effect of DES persisted in male. However, in females both basal LH and FSH levels were rather upregulated and the low ovarian weight returned to the control level.

2. There was no sexual dimorphism in the effect of long-term steroid treatments on PRL secretion. In both female and male rats the PRL release similarly decreased and it was partially prevented after two month and completely after 5-month survival by concomitant P treatment. Removal of DES influence completely restored the PRL release by the end of further 2-month survival. There was a well defined parallel change between the PRL levels and weight of anterior pituitary that was extremely enhanced in DES treated rats and then the enlargement of pituitaries was completely prevented by concomitant P treatment in the case of 5-month survival.

3. A mild sexual dimorphism was also observed in GH level. It was significantly lower only in DES and DES+P treated female, not in male rats with two-month survival. The BW and B+TL were very much depressed by DES treatment in both female and male rats and P little blunted but not prevented this effect. The BW and B+TL in male rats remained low after the removal of DES capsule; however, in females it was nearly similar to intact rats.

4. P alone had no significant effect on the parameters studied; however, the concomitant P treatment with DES was usually protective.

5. Removal of DES capsule reversed the changes in the immunohistochemical appearance of LH, FSH, PRL and GH immunoreactivities.

It is well known that GnRH and LH are released in a cyclic pattern in females but not in male rats. The neural LH release apparatus was demonstrated at the first time by Everett and Sawyer [45,46]. A sexual dimorphism of prepubertal rats in GnRH and LH responses to steroid treatment was also
demonstrated in acute experiments. Dluzen and Ramirez [47] showed that E treated prepubertal females displayed a significant change in GnRH concentrations in the preoptic-suprachiasmatic area upon P treatment; however, males did not show any change. Sexual dimorphism was also observed in the gonadotropin α-subunit promoter activity to GnRH [48]. In the present study we have found sexual dimorphism in the response of basal LH level to long-term DES and P treatments as well.

In our model we did not find any sexual dimorphism in the effect of long-term steroid treatments on PRL secretion and on the weight of pituitaries; however, in other models some sexual dimorphism in the basal level of PRL was observed. It was published earlier that around the time of puberty females had higher PRL mRNA level than males [49], and the weight and PRL level of anterior pituitary in prepubertal females is significantly higher in females than in males [50]. In ovariectomized rats P implanted in silicone tubes subcutaneously induced nocturnal PRL surge, similar P sensitive central mechanism was not observed in adult male rats [51].

A sexual dimorphism was found in the plasma GH pattern and regulation as well. In the above-mentioned experiment it was also demonstrated that around the puberty the males had higher level of GH mRNA than males [49], and the weight and PRL level of anterior pituitary in prepubertal females is significantly higher in females than in males [50]. In ovariectomized rats P implanted in silicone tubes subcutaneously induced nocturnal PRL surge, similar P sensitive central mechanism was not observed in adult male rats [51].

In our model we did not find any sexual dimorphism in the effect of long-term steroid treatments on PRL secretion and on the weight of pituitaries; however, in other models some sexual dimorphism in the basal level of PRL was observed. It was published earlier that around the time of puberty females had higher PRL mRNA level than males [49], and the weight and PRL level of anterior pituitary in prepubertal females is significantly higher in females than in males [50]. In ovariectomized rats P implanted in silicone tubes subcutaneously induced nocturnal PRL surge, similar P sensitive central mechanism was not observed in adult male rats [51].

More data are available about the protective role of P when it is administered with E. The models are very different from what we used. Genazzani and his co-workers [24] studied the role of P and various synthetic progestins in the modulation of the effect of E on hypothalamic GnRH and on pituitary LH and PRL concentrations in ovariectomized rats. And they used only two-week steroid treatment. It was found that P and norethisterone enanthate (NET, synthetic progestin) reversed EB induced hypothalamic GnRH depression, that is elevated its level. Both P and NET blocked the EB induced increase of pituitary LH, and plasma LH levels remained low. Progestins alone did not influence the PRL levels but reversed the EB induced increase. Cho and his co-workers [54] also demonstrated that P suppressed E-enhanced PRL mRNA level.

In our previous experiment it was found that the DES treatment changed not only the number and distribution of tropic hormone producing cells, but the distribution of S-100 immunoreactive folliculostellate cells (FSCs) as well. Inside the prolactinomas FSCs were scattered but they surrounded the prolactinomas forming a demarcation line around them.
[55]. Inside the prolactinomas there were only a few GH cells. When DES was implanted with P the changes, characteristic for DES treatment, could not develop. Concomitant P influence prevented the morphological changes in the anterior pituitary. The distribution of FSCs and GH cells was very similar to that of controls.

In this present experiment in male rats DES permanently injured the gonadotropic functions. After the removal of DES capsule LH and FSH levels, the weight of testis and seminal vesicle remained lower than in controls. Interestingly, in females there was no permanent depression in basal LH and FSH levels and ovarian weight. Rather, both LH and FSH were upregulated. In the literature there is no animal
experiment in which so long steroid treatment was applied and plasma hormone levels were measured. In human medication sexual steroids are used for months to synchronize the ovarian cyclicity, functional dysmenorrhea, premenstrual syndrome, endometriosis and to limit the adult height of girls [56,57].

The question arises how E induces and P prevents the changes caused by a long-term E treatment. As it was mentioned in the introduction ERs and PRs are present not only in the hypothalamus but in the anterior pituitary as well. Steroids can act locally through these receptors on pituitary cells. In a recent publication it was found that ERα is localized in the largest number in lactotropes, and in decreasing number in somatotropes, thyrotropes, gonadotropes. The number of ERβ was much lower and it was identified in somatotropes, lactotropes and gonadotropes [4]. PRA immunoreactivity was seen in the nuclei of gonadotropes [7]. It is also possible that both E and P act through the hypothalamus as well. The distribution of these receptors was recently demonstrated by several authors. Merchenthaler and his co-workers [11] very precisely mapped the distribution of both ERα and ERβ in the hypothalamus. It was found that the density of ERα is very high in the arcuate nucleus and periventricular area and the density of ERβ is high in the paraventricular nucleus and the medial preoptic area where ERβ immunoreactivity colocalize with LHRH immunoreactivity [58]. In the arcuate nucleus colocalization between ERα and GHRH immunoreactivity but not ERα and somatostatin was published by Shimizu et al. [59]. PR containing neurons were demonstrated in the ventrolateral and in the medial part of the arcuate nucleus [10].

The mechanism how the E stimulates the cell proliferation in the anterior pituitary was thoroughly studied [60,61]. It was found that E through ERα induces production of TGF-β3 from lactotropes and this stimulates the bFGF production of FSCs which has a proliferative effect on lactotropes. The mechanism how the concomitant P treatment prevents the E induced proliferation is not fully explored. Calderon and his co-workers [62] used ovariectomized immature rats for analysis of action of P in response of anterior pituitary and hypothalamus to estradiol exposure. E induced the nuclear accumulation of ERs and the appearance of PRs reaching a plateau near the control level. If P was administered to the animals at the peak of ER expression and P can bind directly to these receptors to prevent the production of TGF-β3. 3) The effect of P through the hypothalamus is not excluded. But the above-mentioned experiment indicates that the P acts on the pituitary locally rather than through the hypothalamus.

Acknowledgement

We are grateful to Martin S. Williams (native English speaker) for proofreading and Mária Baláz, Anna Takáts and Isabella Orbán for their technical assistance.

REFERENCES:

1. Morgan WW, Steger RW, Smith MS et al: Time course of induction of PRL-secreting pituitary tumors with diethylstilbestrol in male rats. Response of tuberoinfundibular dopaminergic neurons. Endocrinology, 1985; 116: 17–24
2. Koike S, Sakai M, Muramatsu M: Molecular cloning and characterization of rat estrogen receptor cDNA. Nucleic. Acids Res, 1987; 15: 2499–513
3. Kuiper GJM, Enmark E, Pelto-Huikko M et al: Comparison of ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Proc Natl Acad Sc USA, 1996; 93: 5925–30
4. Gonzales M, Reyes R, Damas C et al: Oestrogen receptor α and β in female rat pituitary cells: An immunohistochemical study. Gen Comp Endocrinol, 2008; 155: 857–68
5. Wilson MF, Price RH Jr, Handa RJ: Estrogen receptor beta messenger ribonucleic acid expression in the pituitary gland. Endocrinology, 1998; 139: 5151–56
6. Szabó M, Kilen SM, Nho SJ, Schwarz NB: Progestosterone receptor A and B messenger ribonucleic acid levels in the anterior pituitary of rats regulated by estrogen. Biol Reprod, 2000; 62: 95–102
7. Garrido-Gracia JC, Gordon A, Bellido C et al: Oestradiol 17β inhibits tamoxifen–induced LHRH self–priming blocking hormone-dependent and ligand independent activation of the gonadotrope progestrone receptor in the rat. J Endocrinol, 2007; 195: 107–19
8. Beintont RA, Thompson RF, Rey MR et al: Progesterone receptors: form and function in brain. Front Neuroendocrinol, 2008; 29: 313–39
9. Guerrera-Araiza C, Cerbon MA, Morimoto S, Camacho-Arroyo I: Progesterone receptor isoforms expression pattern in the rat brain during the estrous cycle. Life Science, 2000; 66: 1743–52
10. Leranth C, Machusky NJ, Brown TJ et al: Transmitter content and afferent connections of estrogen-sensitive gonadotropin-containing neurons in the primate hypothalamus. Neuroendocrinology, 1992; 55: 667–82
11. Merchenthaler I, Lane ML, Numan S, Delovale TL: Distribution of estrogen receptor α and β in the mouse central nervous system: in vivo autoradiographic and immunocytochemical analyses. J Comp Neurol, 2004; 473: 270–91
12. Houben H, Denef C: Bioactive peptides in anterior pituitary cells. Peptides, 1994; 15: 547–82
13. Nagy G, Mulcahey JF, Neill JD: Autocrine control of prolactin secretion by vasoactive intestinal peptide. Endocrinology, 1998; 122: 346–66
14. Schwartz J: Intracellular communication in anterior pituitary. Endocrine Reviews, 2000; 21: 488–513
15. Fink G: Gonadotropin secretion and its control. In Knobil E, Neill J (eds.), The Physiology of Reproduction. New York: Raven Press, 1988; 159–77
16. Goth MI, Lyons CE Jr, Elwood MR et al: Chronic estrogen treatment in male rats reveals mammosomatotropes and allows inhibition of prolactin secretion by somatostatin. Endocrinology, 1996; 137: 274–80
17. Rey-Roldán EB, Grillo CA, Pietranare L et al: Levonorgestrel antagonism of estrogen-induced pituitary tumors is mediated by progesterone receptors. Horm Metab Res, 2008; 40: 245–50
18. Sánchez-Criado JE, Martín De Las Mulas J, Bellido C et al: Biological role of pituitary estrogen receptors ERα and ERβ on gonadotropin and prolactin secretion in the rat. Neuroendocrinology, 2004; 79: 247–58
19. Köves K, Gottschall, PE, Görös TJ et al: Presence of immunoreactive va-
soactive intestinal polypeptide in anterior pituitary of normal male and
long term estrogen-treated female rats: A light microscopic immuno-
histochemical study. Endocrinology, 1990; 126: 1756–63
20. Mantgane MN, Dascalant M, Chew LJ et al: Estradiol induces vasoactive
intestinal peptide and prolactin gene expression in the rat anterior pi-
tuitary independently of plasma prolactin levels. Neuroendocrinology,
1995; 7: 225–31
21. Scully KM, Gleberman AS, Lindzey J et al: Role of estrogen receptor-
alpha in the anterior pituitary gland. Mod Endocrinol, 1997; 11: 674–81
22. Inoah A, Kamui R, Fujii Y, Yokoro K: Protective effects of progesterone
and tamoxifen in estrogen-induced mammary carcinogenesis in ovari-
ectomized W/Fu rats. Jpn. J Cancer Res, 1985; 76: 699–704
23. Meis Pj, Alemen A: Progestogen treatment to prevent preterm birth.
Drugs, 2004; 64: 2463–74
24. Genazzani AR, Petraglia F, Silieri M et al: Progestins modulate the ac-
tion of estrogen on gonadotropin-releasing hormone, luteinizing hor-
mone and prolactin in the rat. Gynecol Obstet Invest, 1990; 29: 197–202
25. Kurzrok R: The prospects for hormonal sterilization. J Contracept, 1973;
2: 27–29
26. Goldzieher JW: The history of steroidal contraceptive development: the
estrogens. Perspect Biol Med, 1995; 38: 363–68
27. Müller-Janncke WD, Ludwig Haberlandt (1885–1932) and the develop-
ment of hormonal contraception. Z Gesamte Inn Med, 1988; 43: 420–22
28. Hatcher RA: Depo-Provera injections, implants, and progestin-only
pills (minipills)”. In: Hatcher RA, Trussel J, Stewart FH et al.: (eds.). Con-
traceptive technology (18th rev. ed.) New York: Ardent Media, 461–94
29. Morad M, Kandel I, Merrick J: Residential care centers for persons with
intellectual disability in Israel: trends in contraception methods 1999–
2006. Med Sci Monit, 2009, 15(6): P417–30
30. Senturk LM, Erel CT: Thin endometrium in assisted reproductive tech-
nology. Curr Opin Obstet Gynecol, 2008; 20: 221–28
31. Szekeres-Bartho J, Balasch J: Progestagen therapy for recurrent miscar-
rriage. Hum Reprod Update, 2008; 14: 27–35
32. Burger H: Hormone replacement therapy in the post-Women’s Health
Initiative era. Report a meeting held in Funchal, Madeira, 2003.
33. Climacteric, 2003; 1: 11–36
34. Tiss LV, Gehallos NA, Chastain G, Tiss RD: Alcohol and estrogen re-
placement therapy in postmenopausal women. Direct and mediated
effects on cognitive component processes. Neuropsychobiology, 2008;
58: 194–10
35. Utah WH, Archer DE, Bachmann GA et al: Estrogen and progestogen
use in postmenopausal women: July 2008 position statement of The
North American Menopause Society. Menopause, 2008; 15: 584–602
36. Oh WK: The evolving role of estrogen therapy in prostate cancer, Clin
Prostate Cancer, 2002; 1: 81–89
37. Demaria JE, Livingston JD, Freeman ME: Ovarian steroids influence
the activity of neuroendocrine dopaminergic neurons. Brain Res, 2006;
1079: 139–47
38. Scammell JG, Scott GM, Outhwaite VA et al: Characterization of mono-
ナル antibodies against ovine prolactin: suitability for use in immunoocy-
tochemical analysis of rat prolactin. J Histochem Cytochem, 1990; 38:
117–22
39. Banik UK, Reves C, Herr F: Ovulation oestrogens and progestins in
prevention of pregnancy in rats. J Reprod Fertil, 1969; 18: 509–15
40. Chang MC, Casa JH, Hunt DM: Prevention of pregnancy in the rab-
bbit by subcutaneous implantation of silastic tube containing oestrogen.
Nature, 1970; 226: 1262–63
41. Mishell DR Jr: Contraception. Am J Dis Child, 1978; 132: 912–20
42. Bigler MO: Adolescent sexual behavior in the eighties. SIECUS Rep,
1989; 18: 6–9
43. Lucky AW, Kohut W, Thiboutot D et al: A combined oral contracep-
tive containing 3-mg drospirenone/20-microg ethinyl estradiol in the
management of acne vulgaris: a randomized, double-blind, placebo-
controlled study evaluating lesion counts and participant self-assessment.
Cutis, 2008; 82: 143–50
44. Merseburger A, Belka C, Behmengen K, Stenzl A: Secondary hormon-
al manipulation. In: Controversies in the Treatment of Prostate Cancer.
Moser L, Schostak M, Miller K, Hinkektein W (eds.), Basel, Karger 2008;
93–102
45. Everett JW, Sawyer CH: A neural timing factor in the mechanism by
which progesterone advances ovulation in the cyclic rat. Endocrinology,
1949; 45: 581–95
46. Everett JW, Sawyer CH: A 24-hour periodicity in the „LH-release appa-
ratus” of female rats disclosed by barbiturate sedation. Endocrinology,
1950; 47: 198–218
47. Džužen DE, Ramirez YD: A functional dimorphism in the response of
the hypothalamic-pituitary axis of prepubertal rats to steroid treatment.
Bioi Reprod, 1982; 27: 456–61
48. Colín IM, Bauer-Dantoin AG, Sundaresan S et al: Sexually dimorphic
transcriptional responses to gonadotropin-releasing hormone require
chronic in vivo exposure to estradiol. Endocrinology, 1996; 137: 2300–7
49. Gonzales Parra S, Clowen JA, Garcia Segura LM, Argente J: Ontogeny
of pituitary transcription factor-I (Pit-1), growth hormone (GH) and pro-
lactin (PRL) mRNA levels in male and female rats and the differential
expression of Pit-1 in lactotrophs and somatotrophs. J Neuroendocrinol,
1996; 8: 211–25
50. Yamamuro Y, Aoki T, Yikawa M, Sensui N: Developmental profile of
prolactin cells in the anterior pituitary of postnatal rats during the lac-
tational stage. Proc Soc Exp Biol Med, 1999; 220: 94–99
51. Kawamimami M, Takahashi M: Induction of daily PRL surges in rats by
chronic treatment with progestrone. Endocrinol Jpn, 1987; 34: 37–44
52. Janson JO, Edén S, Babson O: Sexual dimorphism in the control of
growth hormone secretion. Endocr Rev, 1985; 6: 128–60
53. Nilsson O, Chrysis D, Pañulo O et al: Localization of estrogen receptors-
alpha and -beta and androgen receptor in the human growth plate at
different pubertal stages. J Endocrinol, 2003; 177: 319–26
54. Cho BN, Suh VH, Yoon YD et al: Progestrone inhibits the estrogen-in-
duced prolactin gene expression in the rat pituitary. Mol Cell Endocrinol,
1993; 95: 47–52
55. Heinzlmann A, Köves K: The characteristic change in the distribution
of S-100 immunoimmunoreactive folliculostellate cells in rat anterior pituitary
upon long-term estrogen treatment is prevented by concomitant pro-
gesterone treatment. Endocrine, 2008; 33: 342–48
56. Caufriez A: Menstrual disorders in adolescence: pathophysiology and
treatment. Horm Res, 1991; 36: 156–59
57. Nock W: Indications for the therapeutic use of contraceptive steroids.
Med Welt, 1975; 6: 1509–17
58. Hrabovsky E, Steihauer A, Barabas K et al: Estrogen receptor-beta
immunoreactivity in luteinizing hormone neurons of the rat brain.
Endocrinology, 2001; 142: 3261–64
59. Shimizu T: The estrogen receptor (ER) alpha, but not ER beta, gene is
expressed in hypothalamic growth-hormone-releasing hormone neu-ons of the adult female rat. Neurosci Res, 2005; 52: 121–25
60. Chaturvedi K, Sarkar DK: Involvement of protein kinase C-dependent
mitogen-activated protein kinase pathway in cross-talk between estradiol and
transforming growth factor-beta in increasing basic fibroblast growth factor in
folliculostellate cells. Endocrinology, 2004; 145: 706–15
61. Heines S, Sarkar DK: Transforming growth factor-beta regulation of
estradiol induced prolactinomas. Front Neuroendocrinol, 2001; 22:
340–15